| Drug | Comments |
|---|---|
| ACETAMINOPHEN / CODEINE ELIXIR | |
| ACETAMINOPHEN / CODEINE SUSPENSION | |
| ACETAMINOPHEN WITH CODEINE TABLET | |
| ALFENTANIL INJECTION | |
| CODEINE INJECTION | |
| CODEINE TABLET | |
| FENTANYL 72 HOUR TRANSDERMAL PATCH |
Transdermal fentanyl patches are contraindicated under the following conditions as serious life-threatening hypoventilation may occur: Management of acute or post-operative pain, including use in out patient surgeries. Management of mild or intermittent pain responsive to PRN or non-opioid therapy. Doses exceeding 25 mcg/h at the initiation of therapy in opioid-naïve patients. Children under 12 years of age or patients under 18 years of age who weigh less than 50 kg. |
| FENTANYL INJECTION | Fentanyl PCA |
| HYDROCODONE / ACETAMINOPHEN ELIXIR | |
| HYDROCODONE / ACETAMINOPHEN TABLET | |
| HYDROMORPHONE INJECTION | |
| HYDROMORPHONE TABLET | |
| LEVORPHANOL INJECTION | |
| MEPERIDINE INJECTION | PCA with meperidine doses greater than 10 mg/kg/day is not recommended or therapy for longer than 72 hours in patients with normal renal function. Meperidine is not recommended in patients with renal dysfunction (creatinine clearance < 50 ml/min) or > 65 years old. Oral meperidine has high first pass metabolism, requiring a dose 3 times higher than injectable for equivalent analgesia. Conversion to normeperidine is increased when meperidine is administered by the oral route. Oral meperidine has high first pass metabolism, requiring a dose 3 times higher than injectable for equivalent analgesia. Conversion to normeperidine is increased when meperidine is administered by the oral route. |
| MEPERIDINE INJECTION, PCA 300MG/30ML | |
| MEPERIDINE SYRUP | |
| MEPERIDINE TABLET | |
| METHADONE TABLET | |
| MORPHINE INJECTION | |
| MORPHINE INJECTION, EPIDURAL | |
| MORPHINE INJECTION, PCA 30MG/30ML | |
| MORPHINE SOLUTION | |
| MORPHINE SOLUTION, CONCENTRATE | |
| MORPHINE TABLET | |
| MORPHINE TABLET, SR | |
| OPIUM / BELLADONNA SUPPOSITORY | |
| OXYCODONE TABLET | |
| OXYCODONE SA TABLET | |
| OXYCODONE / ACETAMINOPHEN TABLET | |
| PROPOXYPHENE CAPSULE | Propoxyphene and combination products containing propoxyphene are not recommended for use in pain management due to limited potency and accumulation of toxic metabolites (norpropoxyphene T1/2 39 hours, seizures, cardiac toxicity). Propoxyphene and norpropoxyphene have potent local anesthetic properties. Propoxyphene has a low therapeutic index and deaths have been reported with its use. Propoxyphene appears to display non-linear kinetics; steady state serum levels are 5-7 higher than those obtained after the first dose. Propoxyphene and norpropoxyphene are not removed by dialysis and naloxone is ineffective in treating cardiac toxicity. Alkalinization of the urine decreases propoxyphene excretion by 95%. |
| PROPOXYPHENE / ACETAMINOPHEN TABLET | |
| SUFENTANIL INJECTION | |
| TRAMADOL TABLET | |